DSP 107
Alternative Names: DSP-107; KAHR-107Latest Information Update: 06 Jun 2023
At a glance
- Originator KAHR Medical
- Developer KAHR Medical; Roche
- Class Antineoplastics; Immunotherapies; Proteins; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity; Macrophage stimulants; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
- Preclinical Diffuse large B cell lymphoma
Most Recent Events
- 31 May 2023 Positive efficacy and adverse events data from a phase I/II trial in Solid tumours released by KAHR Medical
- 03 Jun 2022 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 13 Jan 2022 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT04937166)